Increased efficacy of infliximab associated with methotrexate in ankylosing spondylitis

Pérez-Guijo, Verónica; Cravo, Ana Rita; Castro, Maria del Carmen; Font, Pilar; Muñoz-Gomáriz, Elisa; Collantes-Estévez, Eduardo

doi:10.1016/j.jbspin.2006.08.005

Cited by 33 publications

(29 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Most of the studies refer that therapy failure occurred more frequently in positive anti-drug Ab patients [3,32,37,39], although there are previous reports which did not find a similar relation [40][41][42]. It is also reported that the concomitant use of MTX with anti-TNFα drugs reduces the incidence of anti-drug Ab [6,36]; in our study, in agreement with opposite results [13,39] concomitant MTX therapy was irrelevant on anti-drug Ab development.…”

Section: Discussionsupporting

confidence: 85%

“…ETN has shown a less immunogenic effect with anti-etanercept antibodies (anti-ETN Ab) not detectable or present only in a low number of patients; as a consequence anti-ETN immune response has a minimal effect on clinical response [4,[7][8][9]. A clinically relevant impact of anti-drug Ab is described in about half of the patients receiving repeated TNFα monotherapy and therefore immune suppression by concomitant administration of metrotrexate (MTX) is indicated in RA and SpA patients [8,[10][11][12][13][14][15][16][17][18][19][20][21]. Detectable anti-drug Ab decrease TNFα blockers response by as much as 80% [22].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Biologic therapies in rheumatic diseases: drug and anti-drug antibody levels and clinical efficacy

Lombardi¹,

Bernardoni²,

Bertolucci³

et al. 2017

J Autoimmun Cell Response

View full text Add to dashboard Cite

Background: The aim of this study was to evaluate the relevance of drug and anti-drug antibody detection in the clinical management of patients with rheumatoid arthritis (RA) and spondyloarthropaties (SpA) in treatment with anti-tumor necrosis factor alpha (TNFα) biologics. Methods and results:The study included 192 adult consecutive patients treated for at least 6 months with adalimumab (ADA) or etanercept (ETN) or infliximab (IFX); patients underwent clinical observations in the Rheumatologic Unit of 5 Hospitals in Tuscany. Their demographic and clinical characteristics to calculate DAS28 and BASDAI scores were collected. Drug levels and anti-drug antibodies (anti-drug Ab) were evaluated immediately before drug injection or infusion. A total of 192 patients were studied: 62 receiving IFX, 64 ADA, and 66 ETN with a mean age of 57 years (range 18-86 years); the study group was composed of 51% women. Forty percent of the patients were affected by RA, 60% by SpA. Altogether, 81% of patients demonstrated therapeutic drug levels. Anti-drug Ab were found in 19% of patients taking IFX, 10% taking ETN and 5% taking ADA. No significant correlation was found between anti-drug Ab presence and low drug levels, between anti-drug Ab and high DAS28 and BASDAI scores, as well as between low drug levels and high DAS28 and BASDAI scores. Conclusions: Low drug levels were found in 19% of the rheumatic patients and there were not correlations with presence of anti-drug Ab or patient's clinical status.

show abstract

Section: Discussionsupporting

confidence: 85%

Section: Introductionmentioning

confidence: 99%

Biologic therapies in rheumatic diseases: drug and anti-drug antibody levels and clinical efficacy

Lombardi¹,

Bernardoni²,

Bertolucci³

et al. 2017

J Autoimmun Cell Response

View full text Add to dashboard Cite

show abstract

“…Les données disponibles comparant l'infliximab seul et son association au MTXe sont rare et contradictoires [8,9]. Actuellement, selon la Société franç aise de rhumatologie, il n'existe pas de preuve de l'intérêt d'associer un DMARD pour améliorer l'effet des biomédicaments anti-TNF-␣ dans la SpA [10].…”

Section: Association Au Méthotrexateunclassified

Suivi thérapeutique pharmacologique des anti-TNF-α au cours des spondyloarthrites

Mulleman

Goupille

Paintaud

2015

Revue du Rhumatisme Monographies

View full text Add to dashboard Cite

“…Pérez-Guijo et al 5 have previously investigated the potential value of infliximab and methotrexate in comparison to infliximab alone for the treatment of patients with AS. In their openlabel, nonrandomized trial, the nine patients who were administered methotrexate and infliximab responded better than the ten patients given infliximab alone; however, the patients in the combination therapy group were also significantly younger and had shorter disease duration, which are both known predictors for a good response to tumor necrosis factor blockers.…”

Section: Joachim Siepermentioning

confidence: 99%

Infliximab therapy for patients with ankylosing spondylitis: on-demand or continuous treatment?

Sieper

2008

Nat Rev Rheumatol

View full text Add to dashboard Cite

show abstract

Increased efficacy of infliximab associated with methotrexate in ankylosing spondylitis

Cited by 33 publications

References 15 publications

Biologic therapies in rheumatic diseases: drug and anti-drug antibody levels and clinical efficacy

Biologic therapies in rheumatic diseases: drug and anti-drug antibody levels and clinical efficacy

Suivi thérapeutique pharmacologique des anti-TNF-α au cours des spondyloarthrites

Infliximab therapy for patients with ankylosing spondylitis: on-demand or continuous treatment?

Contact Info

Product

Resources

About